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Introduction
Previous studies have demonstrated that serum total
immunoglobulin E (IgE) levels rise in respiratory tract
infections caused by parainfluenza virus, respiratory
syncytial virus (RSV) and rhinoviruses.1 Both IgE and
eosinophil cationic protein (ECP) are important mark-
ers for atopy and allergic inflammation; they are com-
monly used for the diagnosis of and for following the
course of allergic diseases.
Mycoplasma pneumoniae is a common cause of lower
respiratory infection in young children.2–4 The major
clinical symptom of most patients is chronic cough.
Initially, a dry cough is accompanied by thick sputum;
this may persist for several months without adequate
treatment. This presentation is similar to that seen in
patients with asthma. Some studies suggest that the
pathogenic mechanism of action of M. pneumoniae is
due to its specialized attachment tip, the P1 protein,
causing liberation of hydrogen peroxide and inhibition
of host cell catalase activity.5,6 In 1985, Kitahara and
colleagues found that 44% of children with M. pneumo-
niae infection had eosinophilia.7 Yamashita and col-
leagues reported that the serum concentration of ECP
in children with M. pneumoniae infection was higher
than that seen in normal healthy children, and that the
level of serum ECP in children with M. pneumoniae
infection was as high as that seen in children who had
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asthma attacks.8 ECP may play a role in inducing
chronic cough in children with M. pneumoniae infec-
tion. These correlative studies are rarely, if ever, per-
formed in Taiwan. The objective of this study was to
clarify the role of ECP in children with M. pneumoniae
infection.
Methods
Patients
Group 1 consisted of 30 pediatric patients with M. pneu-
moniae infection, without a history of asthma, and
who ranged in age from 4 to 14 years. Blood samples
for serum ECP levels were collected between days 
5 and 20 of infection. The diagnosis of M. pneumo-
niae infection was determined by either a positive
mycoplasma ELISA IgM test or by a 4-fold increase
in the complement fixation test between the acute
and convalescent stages.
Group 2 consisted of 30 pediatric patients with
asthma who ranged in age from 7 to 14 years. These
patients were in a stable condition with no infection,
acute asthma exacerbation or steroid use within the
past 2 months. Blood samples for ECP levels were
collected in the outpatient department.
Group 3 consisted of 30 healthy children who
ranged in age from 3 to 12 years; this was designated
the control group.
Procedure
All blood samples were centrifuged for 10 minutes at
3000 rpm. The serum was collected and immediately
stored at –20°C for further study. Serum ECP levels
were measured using an ECP radioimmunoassay kit
(Pharmacia, Uppsala, Sweden).
Statistical analysis
When the distribution of data sets was normal, the inde-
pendent 2-sample t test was applied to compare the
mean values between 2 groups, and 1-way ANOVA was
performed to compare the mean values between more
than 2 groups. When the data sets were not normally
distributed, the Mann–Whitney U and Kruskal-Wallis
tests were applied to compare the medians in differ-
ent groups. If the means or medians in the groups
were significantly different, then pair-wise multiple
comparisons were performed using the Bonferroni
method.
For a categorical variable, we used the χ2 test to
investigate the homogeneity of the proportion of each
category. In addition, Pearson’s correlation coeffi-
cient was used to measure the strength of the linear
correlation between 2 quantitative variables. All sta-
tistical assessments were 2-sided and evaluated at the
0.05 level of statistical significance. Statistical analyses
were performed using SPSS version 15.0 (SPSS Inc.,
Chicago, IL, USA).
Results
There were 90 children enrolled in this study. Of these,
59 (65.56%) were boys and 31 (34.44%) were girls.
The mean serum ECP levels were not significantly
different between males and females (p = 0.544). The
variance of serum ECP levels decreased as patient age
increased. No obvious trend, pattern or relationship
was noted between serum ECP levels and the children’s
age (r = 0.118, p = 0.267).
We compared the ages, serum ECP levels, and
gender in all 3 groups. The children in the asthma
group tended to be older than the children in the other
2 groups. The ages of the children in the M. pneumo-
niae and control groups were similar. We performed
1-way ANOVA to compare the mean ages among the
3 groups and found a significant difference (p=0.001).
When multiple comparisons were performed with the
Bonferroni method, a significant difference in mean
age between the asthma and control groups was found
(7.11 years vs. 4.53 years).
Figure 1 shows that the serum ECP levels in the
M. pneumoniae and asthma groups were similar, and
that the serum ECP levels in the control group were
lower than those found in the other 2 groups. A sta-
tistically significant difference in serum ECP levels
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Figure 1. Serum eosinophil cationic protein (ECP) levels in
patients with Mycoplasma pneumoniae, patients with asthma,
and normal controls.
was found among the 3 groups (p < 0.001). Both the
asthma and control groups as well as the M. pneumoniae
and control groups had different mean serum ECP
levels. The mean serum ECP levels in the M. pneumo-
niae, asthma and control groups were 28.88 µg/mL,
23.01 µg/mL and 4.48 µg/mL, respectively. Since
gender was a categorical variable, we compared the
proportions of males in the 3 groups using the χ2 test
to evaluate homogeneity. We did not have enough
evidence to conclude that the proportion of males and
females was significantly different among the 3 groups
(p = 0.162).
Discussion
Eosinophilic airway inflammation is a characteristic fea-
ture of asthma.9 ECP is a potent cytotoxic secretory
protein with both bactericidal and antiviral properties;
it reflects the degree of activation of the circulating
eosinophilic pool in the body. Elevated ECP levels
may be found in the serum as well as the bronchoalve-
olar and nasopharyngeal secretions in many diseases,
including asthma, bronchiolitis, atopic dermatitis and
rheumatoid arthritis.
ECP levels may also increase during infection. ECP
levels in the nasopharyngeal secretions of infants with
RSV bronchiolitis were significantly higher than those
found in infants with non-RSV bronchiolitis.10 In
1985, Kitahara et al reported that 44% of children with
asthma-like M. pneumonia infection had eosinophilia.7
The characteristic symptoms of M. pneumoniae infec-
tion are prolonged cough with or without sputum,
which is similar to the symptoms seen with asthma. In
our study, the serum ECP levels in the M. pneumo-
niae and asthma groups were similar; the serum ECP
levels in the control group were lower than those in
the other 2 groups. The activities of ECP as men-
tioned previously include toxic effects on human res-
piratory epithelium seen in vitro and stimulating effects
on human mast cell histamine release.11,12 Kitahara et al
suggested that elevated concentrations of ECP in the
serum of patients with M. pneumonia may be associ-
ated with damaged respiratory epithelium and accel-
erated hypersensitivity in the respiratory system.7 This
may act as a factor in causing persistent cough similar
to asthma in children with M. pneumonia.8 Serum ECP
levels can decrease after treatment with corticosteroids,
as it does also in asthma. Patients with M. pneumoniae
infection have elevated serum levels of ECP and have
clinical symptoms similar to an asthma attack. For this
reason, decreasing the serum level of ECP might play
a role in relieving the symptoms of patients with 
M. pneumoniae infection.
In conclusion, both children with M. pneumoniae
infection and children with asthma have significantly
elevated serum ECP levels compared to normal healthy
children. The elevated serum concentrations of ECP
in patients with M. pneumonia may be associated with
damaged respiratory epithelium and accelerated hyper-
sensitivity in the respiratory system, which may cause
chronic persistent cough for several months. Decreasing
the serum level of ECP might play a role in relieving the
symptoms of patients with M. pneumonia. Additional
studies are warranted to further validate this conclusion.
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